NasdaqGM:SPRYBiotechs
How Does ARS Pharmaceuticals' (SPRY) Neffy Coverage Stall Reframe Its Path to Cash-Flow Break-Even?
Earlier this week, ARS Pharmaceuticals reported that neffy, its epinephrine nasal spray, did not gain any new major commercial insurance coverage in the July 1, 2026 review cycle, though the company did secure additional Medicaid coverage and reduced its planned 2026 cash-based operating expenses.
The update also included management’s reaffirmation that the existing neffy business underpins a path to cash-flow break-even in 2027, underscoring how payer access remains central to the company’s...